G. Wiseman

发表

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Klemens Scheidhauer, Ali Guermazi, Felix M Mottaghy, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.

R. Advani, R. Gascoyne, S. Horning, 2010, Blood.

Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?

G. Wiseman, B. Mullan, C. Gorman, 2000, Thyroid : official journal of the American Thyroid Association.

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

L. Gordon, M. Czuczman, F. Cabanillas, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.

L. Hartmann, P. Anderson, A. Dispenzieri, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Prognostic Value of 2-Deoxy-2-[18F]Fluoro-d-Glucose Positron Emission Tomography in Patients With Suspected Residual or Recurrent Medullary Thyroid Carcinoma

V. Lowe, C. Reading, J. Kasperbauer, 2010, Molecular Imaging and Biology.

Systolic and diastolic cardiac dysfunction early after the initiation of doxorubicin therapy: significance of gender and concurrent mediastinal radiation

I. Clements, G. Wiseman, B. J. Davis, 2002, Nuclear medicine communications.

18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients

B. O'neill, V. Lowe, R. Witte, 2007, Nuclear medicine communications.

Clinical Significance of Diffusely Increased 18F-FDG Uptake in the Thyroid Gland

V. Lowe, G. Wiseman, B. Mullan, 2007, Journal of Nuclear Medicine.

The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.

V. Lowe, E. Georgiou, S. Ansell, 2008, Clinical lymphoma & myeloma.

Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer.

G. Wiseman, B. Mullan, C. Gorman, 2002, The Journal of clinical endocrinology and metabolism.

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.

L. Gordon, J. Murray, T. Witzig, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

D. Podoloff, W. Erwin, T. Witzig, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Long‐term responses in patients with recurring or refractory B‐cell non‐Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

L. Gordon, I. Flinn, R. Macklis, 2007, Cancer.

Assessment of Lymphoma Therapy Using (18)F-FDG PET.

V. Lowe, G. Wiseman, 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

S. Larson, A. Scott, J. Ingle, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study

L. Roberts, G. Wiseman, A. Mahipal, 2020, Expert review of gastroenterology & hepatology.

18F-FDG PET and PET/CT in Burkitt's lymphoma.

V. Lowe, E. Georgiou, G. Wiseman, 2010, European journal of radiology.

Progress in Gene Therapy for Prostate Cancer

B. Davis, G. Wiseman, M. Federspiel, 2012, Front. Oncol..

The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET–CT

V. Lowe, C. Reading, J. Kasperbauer, 2007, Nuclear medicine communications.

NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor

D. Coppola, A. Vinik, V. Go, 2010, Pancreas.

The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs): Well-Differentiated NETs of the Distal Colon and Rectum

A. Benson, D. Klimstra, W. Maples, 2010, Pancreas.

The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.

D. Coppola, L. Kvols, D. Klimstra, 2010, Pancreas.

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma

Sean S. Park, S. Markovic, K. Olivier, 2017, Advances in radiation oncology.

The utility of restaging bone marrow biopsy in PET‐negative patients with diffuse large B‐cell lymphoma and baseline bone marrow involvement

T. Habermann, T. Witzig, G. Wiseman, 2014, American journal of hematology.

Inability of Radioiodine Remnant Ablation to Improve Postoperative Outcome in Adult Patients with Low-Risk Papillary Thyroid Carcinoma.

M. Reinalda, G. Thompson, G. Wiseman, 2021, Mayo Clinic proceedings.

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma

Brian J. Smith, Y. Asmann, T. Habermann, 2013, American journal of hematology.

18F-FDG PET in the management of patients with anaplastic thyroid carcinoma.

V. Lowe, C. Reading, J. Kasperbauer, 2008, Thyroid : official journal of the American Thyroid Association.

A Phase I safety and imaging study using radiofrequency ablation (RFA) followed by 131 I

P. Anderson, G. Wiseman, W. Dunn, 2003 .

Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies

V. Lowe, C. Reading, J. Kasperbauer, 2011, Nuclear medicine communications.

Focal F-18 Fluoro-Deoxy-Glucose Accumulation in the Lung Parenchyma in the Absence of CT Abnormality in PET/CT

G. Wiseman, B. Mullan, R. Subramaniam, 2007, Journal of computer assisted tomography.

Filtered technetium-99m-sulfur colloid evaluated for lymphoscintigraphy.

H. Wahner, G. Wiseman, B. Mullan, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

R. Fonseca, J. Sloan, P. Anderson, 2005, Leukemia.

Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.

L. Gordon, D. Silverman, J. Gutheil, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake after (99m)Tc MAA lung scanning.

T. Therneau, R. Wiesner, G. Wiseman, 2000, Chest.

A Phase II study of 153Sm‐EDTMP and high‐dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

D. Dingli, S. Ansell, A. Dispenzieri, 2010, American journal of hematology.

CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study Durable responses after ibritumomab tiuxetan radioimmunotherapy for

L. Gordon, T. Witzig, G. Wiseman, 2013 .

Safety and efficacy of external beam radiation therapy for non‐Hodgkin lymphoma in patients with prior 90Y‐ibritumomab tiuxetan radioimmunotherapy

T. Witzig, G. Wiseman, J. Martenson, 2006, Cancer.

Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.

L. Gordon, J. Murray, N. Bartlett, 2004, Cancer biotherapy & radiopharmaceuticals.

Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition.

G. Gores, N. LaRusso, D. Nagorney, 1995, Gastroenterology.

A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non–Hodgkin's Lymphoma: A Children's Oncology Group Study

S. Perkins, A. Angiolillo, P. Adamson, 2007, Clinical Cancer Research.

Risk of histological transformation and therapy‐related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma

T. Habermann, S. Ansell, S. Markovic, 2017, British journal of haematology.

Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma

G. Wiseman, I. Micallef, P. Johnston, 2008, Bone Marrow Transplantation.

Low toxicity and efficacy of 153samarium‐EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia

P. Anderson, G. Wiseman, C. Arndt, 2005, Pediatric transplantation.

High-Dose S amarium-153 E thylene D iamine Tetramethylene P hosphonate: L ow T oxicity o f S keletal Irradiation i n P atients W ith O steosarcoma a nd B one Metastases

L. Hartmann, P. Anderson, A. Dispenzieri, 2002 .

Late recurrence and rapid evolution of severe hepatopulmonary syndrome after liver transplantation.

R. Wiesner, G. Wiseman, M. Krowka, 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods.

A. Tefferi, J. Hoyer, G. Wiseman, 1996, Blood cells, molecules & diseases.

Usefulness of 123I-MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter Trial

D. Mankoff, K. Pacak, G. Wiseman, 2009, Journal of Nuclear Medicine.

in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter Trial

D. Mankoff, K. Pacak, G. Wiseman, 2009 .

Usefulness of 123 I-MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma : Results from a Prospective Multicenter Trial

D. Mankoff, K. Pacak, G. Wiseman, 2009 .

A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer 1

S. Larson, A. Scott, J. Ingle, 2003 .

Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma

S. Shen, A. Forero, G. Wiseman, 2010, Journal of Nuclear Medicine.

Radiation dosimetry results for zevalin radioimmunotherapy of rituximab‐refractory non‐hodgkin lymphoma

D. Silverman, W. Erwin, T. Witzig, 2002, Cancer.

Safety o f Y ttrium-90 I britumomab T iuxetan Radioimmunothera py f or R elapsed L ow-Grade, F ollicular, o r Transformed N on-Hodgkin's L ymphoma

L. Gordon, J. Murray, T. Witzig, 2003 .

Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404

R. Advani, R. Gascoyne, S. Horning, 2008 .

18F-fluorodeoxyglucose positron emission tomography/computed tomography of giant cell arteritis with lower extremity involvement in association with polymyalgia rheumatica

G. Johnson, G. Wiseman, A. Panda, 2020, World journal of nuclear medicine.

Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia

P. Anderson, G. Wiseman, C. Arndt, 2006, Leukemia & lymphoma.

Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma

L. Gordon, I. Flinn, T. Witzig, 2006, Leukemia & lymphoma.

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.

L. Gordon, T. Witzig, G. Wiseman, 2004, Blood.

Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma – tissue remains the issue

A. Feldman, T. Habermann, T. Witzig, 2017, Leukemia & lymphoma.

Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.

G. Wiseman, W. Dunn, M. Stabin, 2003, Cancer biotherapy & radiopharmaceuticals.

UPDATE ON IDEC-Y2B8 (ZEVALIN) RADIOIMMUNOTHERAPY OF B-CELL NHL

L. Gordon, T. Witzig, G. Wiseman, 1999 .

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.

L. Gordon, D. Silverman, J. Gutheil, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibritumomab tiuxetan radioimmunotherapy for Primary Gastrointestinal Follicular Lymphoma.

G. Wiseman, Sanjal H Desai, T. Witzig, 2021, The oncologist.

Contribution of F-18 FDG PET-CT in the Detection of Systemic Spread of Primary Central Nervous System Lymphoma

B. O'neill, R. Witte, G. Wiseman, 2007, Clinical nuclear medicine.

Conventional treatments for non-Hodgkin's lymphoma: the need for new therapies.

G. Wiseman, C. White, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Hepatic vein tumor thrombus as a risk factor for excessive pulmonary deposition of microspheres during TheraSphere therapy for unresectable hepatocellular carcinoma.

L. Roberts, G. Wiseman, J. Andrews, 2009, Journal of vascular and interventional radiology : JVIR.

Langerhans cell histiocytosis

B P Mullan, J. Edmonson, G. Wiseman, 1999, Cancer.

The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma.

A. Weaver, G. Wiseman, R. Roenigk, 2012, Journal of the American Academy of Dermatology.

Steroid action on gene expression: possible roles of regulatory genes and nuclear acceptor sites.

G. Wiseman, T. Spelsberg, J. Rejman, 1989, Biology of reproduction.

Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing.

G. Denardo, S. Denardo, M. Juweid, 2001, Critical reviews in oncology/hematology.

Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Deborah A. Bowen, S. Slager, G. Wiseman, 2014, Leukemia & lymphoma.

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Deborah A. Bowen, A. Feldman, T. Habermann, 2017, Blood.

Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma

P. Anderson, G. Wiseman, V. Rodriguez, 2005, Clinical Cancer Research.

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

L. Gordon, M. Czuczman, I. Flinn, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma

J. Buckner, L. Hartmann, G. Wiseman, 1995, Cancer.

Sensitivity and Utility of Parathyroid Scintigraphy in Patients with Primary Versus Secondary and Tertiary Hyperparathyroidism

T. Sebo, G. Wiseman, B. Mullan, 2006, World Journal of Surgery.

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.

T. Habermann, S. Ansell, T. Witzig, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone scintigraphy evaluated in diagnosing and staging Langerhans' cell histiocytosis and related disorders.

G. Wiseman, B. Mullan, W. Dunn, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

the treatment of myelofibrosis with myeloid metaplasia A phase 2 trial of combination low-dose thalidomide and prednisone for

D. Steensma, R. Mesa, A. Tefferi, 2012 .

A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.

A. Scott, J. Ingle, A. Papenfuss, 2007, Cancer immunity.

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

B. B. Weitner, A. Rademaker, L. Gordon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.

L. Gordon, I. Flinn, T. Witzig, 2007, Cancer biotherapy & radiopharmaceuticals.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

L. Gordon, J. Murray, N. Bartlett, 2002, Blood.

multicenter trial refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or

L. Gordon, J. Murray, T. Witzig, 2013 .

Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues.

L. Kvols, G. Wiseman, G A Wiseman, 1995, Seminars in nuclear medicine.

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

J. Vose, B. Cheson, F. Mottaghy, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.

L. Gordon, M. Czuczman, I. Flinn, 2002, Seminars in oncology.

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma

Daniel H. S. Silverman, Stewart Spies, William L. Dunn, 2000, European Journal of Nuclear Medicine.

Patients Enrolled in the Gimema Lal 0496 Protocol Presentation and Correlation with Response to Induction Treatment in Adult T-cell Acute Lymphoblastic Leukemia: Biologic Profile At

T. Habermann, M. Vignetti, A. Guarini, 2005 .

Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.

T. Witzig, G. Wiseman, Thomas E Witzig, 2005, Cancer biotherapy & radiopharmaceuticals.

Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.

L. Gordon, M. Czuczman, N. Bartlett, 2004, Clinical lymphoma.

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

D. Steensma, R. Mesa, S. Kaufmann, 2003, Blood.

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

J A Parker, W D Erwin, D. Podoloff, 2001, Critical reviews in oncology/hematology.

Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma.

H. Tun, T. Witzig, G. Wiseman, 2022, Clinical lymphoma, myeloma & leukemia.

Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy

T. Habermann, S. Ansell, T. Witzig, 2011 .

18F FDG PET/CT imaging of primary extradrenal paragangliomas

V. Lowe, G. Wiseman, B. Mullan, 2006 .

Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

L. Gordon, P. Conti, D. Silverman, 2007, Clinical lymphoma & myeloma.

Final Results of a Randomized Controlled Study of the Ibritumomab Tiuxetan Radioimmunotherapy Regimen vs a Standard Course of Rituximab Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma

L. Gordon, M. Czuczman, J. Murray, 2001 .

Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma

T. Therneau, G. Gores, N. LaRusso, 2013, CardioVascular and Interventional Radiology.

Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.

P. Conti, H. Wagner, G. Wiseman, 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Outcome prediction in heart failure with atrial fibrillation: Relative role of left ventricular ejection fraction and neurohormonal measures

I. Clements, D. Hodge, G. Wiseman, 2013, Journal of Nuclear Cardiology.

Evaluation of macroaggregated albumin particle sizes for use in pulmonary shunt patient studies.

J C Hung, G. Wiseman, D. Mahoney, 2000, Journal of the American Pharmaceutical Association.

90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

A. Rademaker, L. Gordon, J. Winter, 2006 .

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.

D. Podoloff, W. Erwin, N. Bartlett, 2003, Cancer biotherapy & radiopharmaceuticals.

Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study.

A. Benson, J. Geschwind, M. Mulcahy, 2013, European journal of cancer.

Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study

P. Marchetti, V. Suman, S. Markovic, 2018, Oncotarget.

A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).

T. Habermann, T. Shanafelt, S. Ansell, 2007 .

Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma with Zevalin, a 9~ Anti-CD20 Monoclonal Antibody 1

L. Gordon, D. Silverman, J. Gutheil, 1999 .

Liver transplantation after radioembolization in a patient with unresectable HCC

L. Roberts, P. Kwo, G. Wiseman, 2009, Nature Reviews Gastroenterology &Hepatology.

Measuring granulocyte and monocyte accumulation at malignant lymphoma sites.

S. Horning, M. Juweid, G. Wiseman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.

P. Kurtin, T. Habermann, T. Witzig, 2011, Blood.

Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated ( High-Grade ) Extrapulmonary Neuroendocrine Carcinomas

D. Coppola, L. Kvols, D. Klimstra, 2010 .

A Prospective Study of Relationships Between Severity of Liver Disease, PaO 2 Response to 100% Oxygen, and Brain Uptake After 99m Tc MAA Lung Scanning

T. Therneau, R. Wiesner, G. Wiseman, 2015 .

NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor

D. Coppola, A. Vinik, V. Go, 2010, Pancreas.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

L. Gordon, J. Murray, N. Bartlett, 2002, Blood.